286 related articles for article (PubMed ID: 32089220)
21. [Significance of somatic mutations on the prognosis of myelodysplastic syndromes].
Yoshizato T
Rinsho Ketsueki; 2018; 59(8):1078-1085. PubMed ID: 30185709
[TBL] [Abstract][Full Text] [Related]
22. Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.
Fang K; Qi J; Zhou M; Zhang Z; Han Y
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):224-235. PubMed ID: 34690091
[TBL] [Abstract][Full Text] [Related]
23. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
DiGennaro J; Sallman DA
Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
[TBL] [Abstract][Full Text] [Related]
24. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
25.
Cumbo C; Tota G; Anelli L; Zagaria A; Specchia G; Albano F
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414002
[No Abstract] [Full Text] [Related]
26. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
[TBL] [Abstract][Full Text] [Related]
27.
Santini V; Stahl M; Sallman DA
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424
[No Abstract] [Full Text] [Related]
28. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Chang CK; Zhao YS; Xu F; Guo J; Zhang Z; He Q; Wu D; Wu LY; Su JY; Song LX; Xiao C; Li X
Br J Haematol; 2017 Feb; 176(4):600-608. PubMed ID: 27984642
[TBL] [Abstract][Full Text] [Related]
29. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
Kojima K
Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
[TBL] [Abstract][Full Text] [Related]
31. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
32. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?
Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2020 Oct; 13(10):1131-1142. PubMed ID: 32876498
[TBL] [Abstract][Full Text] [Related]
33. [Clinical Characteristics and Karyotype Analysis of Myelodysplastic Syndrome Patients with TP53 mutation].
Zhou XY; Ouyang GF; Mu QT; Sheng LX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):872-876. PubMed ID: 31204947
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
Siddon AJ; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
[TBL] [Abstract][Full Text] [Related]
35. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.
Haider M; Duncavage EJ; Afaneh KF; Bejar R; List AF
Am Soc Clin Oncol Educ Book; 2017; 37():480-494. PubMed ID: 28561687
[TBL] [Abstract][Full Text] [Related]
36. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
[TBL] [Abstract][Full Text] [Related]
38. TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.
Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Yim SH; Kim HJ; Kwon YR; Jeon YW; Lee SH; Chung YJ; Lee JH
Leuk Res; 2018 Nov; 74():97-104. PubMed ID: 30343213
[TBL] [Abstract][Full Text] [Related]
39. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract][Full Text] [Related]
40. Analysis of clinical and molecular features of MDS patients with complex karyotype in China.
Ren Y; Mei C; Ye L; Luo Y; Zhou X; Yang H; Lin P; Xu W; Ma L; Jin J; Tong H
Blood Cells Mol Dis; 2019 Mar; 75():13-19. PubMed ID: 30530101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]